Fundamental Analysis of Oramed Pharmaceuticals Inc - Growth / Value Index
ORMP - Valuation Highlights
Valuation Analysis
Tsr Value Index - Very Poor Score of 10.94
Price to Book Ratio of 246.50 suggesting that it is very expensive
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | 1556.41 | -2.25 | 4.57 % | |
| Price to Book | 233.64 | 0.562 | 100.00 % | 0.533 |
| Price to Sales | 32624.59 | 31.45 | -1.43 % | |
| Enterprise Value to EBITDA Multiple | 2.86 | -1.21 | 43.03 % |
ORMP - Profitability Highlights
Profitability Analysis
During the past twelve months, the company has given a strong Net Margin of 2096.14%
Piotroski F Score - Stable Value of 4.0
Tsr Profitability Index - Very Poor Score of 15.62
Very Low Dividend Yield of 0 %
Negative Net profit for last two years
In the last three years, the company has given poor Net Margin
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | 9.02 | -24.88 | 99.90 % | 0.922 |
| Return On Asset | 10.62 | -23.36 | 100.00 % | 0.754 |
| Net Profit Margin | 2096.14 | -1397.11 | -3.29 % | 0 |
| Operating Profit Margin | -1076.26 | -1501.96 | 0 % | 0 |
| EBITDA Margin | 2510.39 | -1367.96 | 8.79 % | 0 |
Highlights
| Market Cap | 88571.00 K |
| Enterprise Value | 48354.00 K |
| Price/Book TTM | 233.64 |
| Outstanding Share | 40628.90 K |
| Float/ Outstanding Share | 90.59% |
| Dividend Yield | 0 % |
Share Holding
Guru Numbers
| Price/Graham No | 6.24 |
| Peter Lynch Ratio | 0 |
| Piotroski F Score | 4.00 |
| Altman Z Score | 3.73 |
| Sloan Ratio | -0.061 |
| Peter Lynch Fair Value | 0 |
ORMP - Growth Highlights
Growth Analysis
Steady increase in Total Assets for last 3 Years
Tsr Growth Index - Very Poor Score of 11.36
Quarterly sales in last 5 Quarter is trending down
Annual sales in last 3 years is trending down
Operating Cash Flow decreasing for last 3 year
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 674000 | 0 % | % |
| Gross Profit | 674000 | % | % |
| EBITDA | 16920.00 K | 8.79 % | 85.04 % |
| Net Profit | 14128.00 K | 3.29 % | 88.48 % |
| EPS | 0.0014 | 4.79 % | NA |
ORMP - Stability Highlights
Stability Analysis
Altman Z Score of 4.01 suggests good Stability
Cash ratio of 27.10
Company financial liquidity has improved
Company is unable to generate enough free cash to support the business.
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 0.0016 | 9.76 % | 0 |
| Cash Ratio | 27.10 | 360.14 % | |
| Quick Ratio | 0 | 0 % | 5.28 |
| Shareholders Equity | 93.92 | -97.40 % | |
| Debt to EBITDA | -0.0067 | -118675.24 % |
Historical Valuation Ratios of Oramed Pharmaceuticals Inc
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Oramed Pharmaceuticals Inc
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Oramed Pharmaceuticals Inc
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Oramed Pharmaceuticals Inc
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)